Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 10 Dec 2013 |
| Orion Oyj: SHARE REPURCHASE December 9, 2013 | 9 Dec 2013 |
| Orion settles patent dispute over the proprietary drug Precedex® | 5 Dec 2013 |
| Orion Corporation: SHARE REPURCHASE December 5, 2013 | 5 Dec 2013 |
| Orion Corporation: SHARE REPURCHASE December 4, 2013 | 4 Dec 2013 |
| Orion Corporation: SHARE REPURCHASE December 3, 2013 | 3 Dec 2013 |